Olmesartan Medoxomil Mylan

Olmesartan Medoxomil, the active ingredient in Olmesartan Medoxomil Mylan, is an Angiotensin II receptor blocker presented as an oral tablet for oral use. It treats hypertension in adult patients. GNH USA supplies Olmesartan Medoxomil Mylan as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Olmesartan Medoxil is used to manage hypertension, a condition characterized by elevated arterial pressure. - Hypertension: lowers blood pressure by blocking the effects of angiotensin II, helping to reduce the risk of cardiovascular events. - Essential hypertension: provides sustained blood pressure control in patients requiring long‑term therapy. - Primary hypertension: improves vascular tone and reduces cardiac workload.

Common Side Effects: - Dizziness: sensation of light‑headedness, especially after standing. - Headache: mild to moderate pain in the head region. - Fatigue: feeling unusually tired or lacking energy. - Abdominal pain: discomfort or cramping in the stomach area. Serious or Rare Side Effects: - Angioedema: swelling of the face, lips, tongue, or throat that may impair breathing. - Hyperkalemia: elevated potassium levels that can affect heart rhythm. - Renal impairment: worsening kidney function, indicated by increased creatinine. - Severe hypotension: markedly low blood pressure causing faintness or shock.

Olmesartan Medoxomil requires careful monitoring and patient education. - Blood pressure monitoring: regularly check to ensure therapeutic effect and avoid excessive lowering. - Renal function assessment: evaluate kidney function before initiating and during therapy. - Serum potassium check: monitor potassium levels, especially when combined with potassium‑sparing agents. - Pregnancy avoidance: do not use during pregnancy due to risk of fetal toxicity. - Elderly caution: start at lower doses and monitor for orthostatic hypotension. - Store at room temperature: keep in the original packaging, protect from moisture and direct sunlight.

Olmesartan Medoxomil may interact with several drug classes. Major Interactions (Avoid): - Aliskiren (in diabetic patients): combined use can increase risk of renal dysfunction. - Potassium‑sparing diuretics (e.g., spironolactone): may cause dangerous hyperkalemia. - ACE inhibitors (e.g., enalapril): concurrent use heightens risk of hypotension and hyperkalemia. - NSAIDs (e.g., ibuprofen): can blunt antihypertensive effect and affect renal function. Moderate Interactions (Monitor Closely): - Thiazide diuretics: may enhance blood‑pressure‑lowering effect, requiring dose adjustment. - Lithium: can increase lithium levels, necessitating serum monitoring. - Other antihypertensives (e.g., beta‑blockers): may require careful titration to avoid excessive hypotension.